PureTech Health 2025 annual results: plenty of progress, but the market will focus on execution
PureTech Health has used its 2025 annual results to make one thing very clear: this is now a leaner, more focused business. The company is sharpening its strategy around pushing assets to key value-inflection points, then bringing in external capital to fund the heavier lifting.
That matters because biotech investors often get punished for two things – spending too much and trying to do too much. PureTech is trying to tackle both at once, while keeping exposure to the upside from its portfolio.
| Key figure | 2025 | 2024 |
|---|---|---|
| PureTech level cash, cash equivalents and short-term investments | $277.1 million | $366.8 million |
| PureTech level cash and cash equivalents at March 31, 2026 | $248.1 million | Not disclosed |
| Total revenue | $4.7 million | $4.8 million |
| General and administrative expenses | $46.6 million | $71.5 million |
| Research and development expenses | $56.6 million | $69.5 million |
| Net loss attributable to owners of the Group | $109.7 million | Profit of $53.5 million |
| Operational runway | At least through end 2028 | Not disclosed here |
Why PureTech’s headline loss looks ugly, but the underlying cost trend is better
The big red flag on first glance is the swing from a profit of $53.5 million in 2024 to a net loss of $109.7 million in 2025. On the face of it, that is rough. But the detail matters here.
2024 included a one-off gain of $151.8 million from the deconsolidation of Seaport. That did not repeat in 2025. So part of the year-on-year drop is simply the absence of a big accounting boost.
There was also a nasty-looking non-cash finance cost of $43.9 million linked to the sale of future royalties. In plain English, PureTech had to revalue the liability tied to royalties sold to Royalty Pharma because forecasts for Cobenfy sales changed. That hits accounting profit, but it is not the same as a straight cash cost leaving the business today.
The more encouraging bit is lower operating spend. General and administrative costs fell 35% to $46.6 million, while research and development costs fell 19% to $56.6 million. Net cash used in operating activities also improved to $85.1 million from $134.4 million.
My take: this is one of those results where the statutory loss looks worse than the operating direction. For retail investors, that distinction is important.
Celea Therapeutics and deupirfenidone: the Phase 3 funding close is the next big share price catalyst
The standout asset is Celea Therapeutics’ deupirfenidone for idiopathic pulmonary fibrosis, or IPF, a serious lung disease. PureTech says the drug is now Phase 3-ready, which is a big step up in potential value if the next trial gets under way.
The funding piece is critical. Celea has secured sufficient non-binding commitments from external investors, alongside participation from PureTech, so the fundraising is described as “substantially complete”, subject to continued negotiations.
The target is to close that financing by early in the third quarter of 2026. If it lands on time, Celea expects the Phase 3 SURPASS-IPF trial to start in close proximity to closing.
This is good news, but it is not banked yet. “Non-binding commitments” are helpful, not final. That means investors should treat this as promising rather than done.
Still, if Celea gets funded externally, PureTech expects its operational burn to reduce significantly. That is a very big deal because it means the parent company can stay lean while still owning the upside.
Gallop Oncology and Seaport Therapeutics: more validation, but more financing risk too
Gallop Oncology also moved forward. PureTech reported positive topline data in April 2026 from the completed Phase 1b trial of LYT-200 in heavily pretreated patients with relapsed or refractory high-risk myelodysplastic syndrome and acute myeloid leukaemia.
Gallop has selected a recommended Phase 2 dose and plans to speak to the FDA about a trial design that could potentially support registration in relapsed or refractory high-risk myelodysplastic syndrome. The catch is funding. Gallop wants third-party capital for that next stage, with the round targeted to close in the first quarter of 2027.
Seaport is a bit different because PureTech owns 35.0% equity, plus tiered royalties of 3-5% on Glyph product net sales and modest milestone payments. The company reported positive topline data from part of the Phase 1 GlyphAgo study and Seaport has publicly filed for a potential US IPO.
But again, nothing is final. The timing, number of shares and price range for the Seaport offering were not disclosed. So there is progress here, but also the usual biotech financing uncertainty.
Nasdaq delisting plan: a sensible cost-saving move, with one obvious downside
One of the more eye-catching announcements is PureTech’s intention to voluntarily delist its American Depositary Shares from Nasdaq and focus on the London Stock Exchange. Management says most trading volume and liquidity already sit in London.
I think this is broadly sensible. Dual listings can sound impressive, but if one market is not doing much for liquidity or valuation, it can just become an expensive administrative headache.
The downside is visibility. A Nasdaq listing can help attract US specialist biotech investors, and losing it may narrow the audience a bit. The company clearly thinks the cost savings and simplification outweigh that trade-off.
The timing of the delisting was not disclosed in this announcement.
PureTech cash runway and shareholder returns: strong balance sheet, but delivery now matters most
PureTech ended 2025 with $277.1 million of PureTech level cash, cash equivalents and short-term investments, a non-IFRS measure that excludes cash at a non-wholly owned subsidiary. By March 31, 2026, PureTech level cash and cash equivalents were $248.1 million.
That still supports management’s claim of operational runway through at least the end of 2028, including expected participation in Founded Entity fundraisings. In biotech, that kind of runway gives you breathing room. It also reduces the fear of a near-term emergency raise at the parent level.
The other line investors will like is shareholder returns. PureTech says it will look to return a greater proportion of future cash generation to shareholders, particularly in the event of outsized returns, and notes that $150.0 million has already been returned to date.
That is encouraging, but I would not overplay it yet. Right now, the market is likely to care more about Celea funding, Gallop financing plans, Seaport progress and whether the lower-cost model actually sticks.
What PureTech Health’s 2025 results mean for retail investors
My overall view is cautiously positive. PureTech has real assets, a decent cash buffer, and a strategy that makes more sense than trying to bankroll everything itself.
The best part of this RNS is the discipline. The weakest part is that a lot of the value story still depends on external financings closing on time. That means the science looks increasingly validated, but the corporate execution still has to catch up.
For shareholders, this is now a much clearer investment case. PureTech is betting it can create value by being a capital-efficient biotech builder rather than an overextended drug developer. If Celea closes its financing and Phase 3 starts as planned, that could go a long way towards proving the model works.
